A structural view of the antibiotic degradation enzyme NDM-1 from a superbug

Gram-negative Enterobacteriaceae with resistance to carbapenem conferred by New Delhi metallo-β-lactamase 1 (NDM-1) are a type of newly discovered antibioticresistant bacteria. The rapid pandemic spread of NDM-1 bacteria worldwide (spreading to India, Pakistan, Europe, America, and Chinese Taiwan) in less than 2 months characterizes these microbes as a potentially major global health problem. The drug resistance of NDM-1 bacteria is largely due to plasmids containing the blaNDM-1 gene shuttling through bacterial populations. The NDM-1 enzyme encoded by the blaNDM-1 gene hydrolyzes β-lactam antibiotics, allowing the bacteria to escape the action of antibiotics. Although the biological functions and structural features of NDM-1 have been proposed according to results from functional and structural investigation of its homologues, the precise molecular characteristics and mechanism of action of NDM-1 have not been clarified. Here, we report the three-dimensional structure of NDM-1 with two catalytic zinc ions in its active site. Biological and mass spectroscopy results revealed that D-captopril can effectively inhibit the enzymatic activity of NDM-1 by binding to its active site with high binding affinity. The unique features concerning the primary sequence and structural conformation of the active site distinguish NDM-1 from other reported metallo-β-lactamases (MBLs) and implicate its role in wide spectrum drug resistance. We also discuss the molecular mechanism of NDM-1 action and its essential role in the pandemic of drug-resistant NDM-1 bacteria. Our results will provide helpful information for future drug discovery targeting drug resistance caused by NDM-1 and related metallo-β-lactamases.

[1]  R. Moellering NDM-1--a cause for worldwide concern. , 2010, The New England journal of medicine.

[2]  J. Frère,et al.  The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. , 1995, The EMBO journal.

[3]  S. Owusu-Agyei,et al.  The need for new antibiotics , 2010, The Lancet.

[4]  Seiki Kuramitsu,et al.  The first crystal structure of an archaeal metallo‐β‐lactamase superfamily protein; ST1585 from Sulfolobus tokodaii , 2010, Proteins.

[5]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[6]  K Henrick,et al.  Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. , 2004, Acta crystallographica. Section D, Biological crystallography.

[7]  O. Dideberg,et al.  The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. , 2008, Journal of molecular biology.

[8]  H Toh,et al.  Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold. , 2001, FEBS letters.

[9]  S. Chihara,et al.  First case of New Delhi metallo-beta-lactamase 1-producing Escherichia coli infection in Japan. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Timothy R. Walsh,et al.  Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India , 2009, Antimicrobial Agents and Chemotherapy.

[11]  D. Livermore Has the era of untreatable infections arrived? , 2009, The Journal of antimicrobial chemotherapy.

[12]  B. Matthews Solvent content of protein crystals. , 1968, Journal of molecular biology.

[13]  J. Frère,et al.  Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. , 2000, Biochemistry.

[14]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[15]  C. Bebrone Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. , 2007, Biochemical pharmacology.

[16]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[17]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[18]  Hiromi Daiyasu,et al.  Expansion of the zinc metallo‐hydrolase family of the β‐lactamase fold , 2001 .

[19]  J. Frère,et al.  Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. , 2010, Journal of medicinal chemistry.

[20]  T. Walsh Emerging carbapenemases: a global perspective. , 2010, International journal of antimicrobial agents.

[21]  Robert M. Sweet,et al.  Macromolecular Crystallography: Part A , 1997 .

[22]  K. Lee,et al.  Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? , 1998, Yonsei medical journal.

[23]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[24]  J. Frère,et al.  The 3‐D structure of a zinc metallo‐beta‐lactamase from Bacillus cereus reveals a new type of protein fold. , 1995 .

[25]  D. Livermore,et al.  Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. , 2011, The Lancet. Infectious diseases.

[26]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[27]  J. Giesecke,et al.  New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[28]  Göran Tomson,et al.  Antibiotic resistance in China—a major future challenge , 2009, The Lancet.

[29]  J. Frère,et al.  Three-dimensional structure of FEZ-1, a monomeric subclass B3 metallo-beta-lactamase from Fluoribacter gormanii, in native form and in complex with D-captopril. , 2003, Journal of molecular biology.

[30]  Gianfranco Amicosante,et al.  The 1.5-Å Structure of Chryseobacterium meningosepticum Zinc β-Lactamase in Complex with the Inhibitor, D-Captopril* , 2003, Journal of Biological Chemistry.

[31]  E. Abraham,et al.  Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. , 1966, The Biochemical journal.

[32]  E. Abraham,et al.  An Enzyme from Bacteria able to Destroy Penicillin , 1940, Nature.

[33]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[34]  Carine Bebrone,et al.  A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. , 2005, Journal of molecular biology.

[35]  J. Frère,et al.  Analysis of the importance of the metallo-beta-lactamase active site loop in substrate binding and catalysis. , 2003, Chemistry & biology.

[36]  JENS ANTONY,et al.  Binding of D‐ and L‐captopril inhibitors to metallo‐β‐lactamase studied by polarizable molecular mechanics and quantum mechanics , 2002, J. Comput. Chem..